Artificial Intelligence (AI) opens new horizons in the understanding, diagnosis and treatment of leukaemia Published on 04/10/2023 During the 12th edition of their Open Days, experts from MD Anderson in Houston and other national and international specialists presented some of the latest developments in this field to the participants.
Research into acute leukemia moves towards "tailor-made" treatments for each individual patient Published on 22/11/2022 Research into acute leukemia is currently one of the most active fields in Spain due to the shortcomings persisting in the treatment of these patients, who amount to more than 6,000 every year1
Improves the identification of genetic alterations in leukemia, allowing treatment to be personalized, improving its effectiveness Published on 20/06/2022 Depending on the type of leukemia, patients will have different genetic alterations or mutations that determine the progress of treatment
Hematologists face the challenge of incorporating Target Therapies into daily practice in the treatment of acute leukemia Published on 10/11/2021 Better understanding of cell tumor biology opens possibilities for targeted therapies in acute leukemia
Systemic mastocytosis, a disease of rare diagnosis, to be studied at the 10th Acute Leukemia Conference of MD Anderson Madrid Published on 27/09/2021 It will feature prominent speakers from different countries in America and Europe, as well as the intervention of professionals from the MD Anderson leukemia department in Houston
A decade of hope begins for the treatment of acute myeloid leukemia thanks to new treatments like FLT3 inhibitors Published on 21/06/2021 New drugs, like FLT3 inhibitors, improve survival rates in people with acute myeloid leukemia, acting on altered intracellular signaling pathways that allow cancer cells to grow
IDH inhibitors give very positive results in relapsed acute myeloblastic leukemia patients with the mutation Published on 08/10/2019 Acting on this therapy target would give favorable results in both monotherapy and in combination with other agents, thus improving life expectancy of patients with acute myeloblastic leukemia (AML)
MD Anderson Cancer Center Madrid and emov join forces to build awareness among the public in Madrid of the effects of airborne pollution on the health Published on 15/11/2018 Published November 15 2018